Raiffeisen Bank International AG Makes New $1.03 Million Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Raiffeisen Bank International AG bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 15,658 shares of the biotechnology company's stock, valued at approximately $1,025,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Point72 Europe London LLP bought a new position in BioMarin Pharmaceutical in the fourth quarter valued at about $3,993,000. Polar Asset Management Partners Inc. acquired a new position in BioMarin Pharmaceutical during the 4th quarter valued at about $979,000. Quantinno Capital Management LP bought a new position in shares of BioMarin Pharmaceutical in the 4th quarter valued at about $384,000. Nissay Asset Management Corp Japan ADV boosted its stake in shares of BioMarin Pharmaceutical by 1.5% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 23,253 shares of the biotechnology company's stock valued at $1,555,000 after purchasing an additional 334 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp grew its position in shares of BioMarin Pharmaceutical by 20.4% during the 4th quarter. OMERS ADMINISTRATION Corp now owns 7,895 shares of the biotechnology company's stock worth $519,000 after buying an additional 1,340 shares during the period. Institutional investors own 98.71% of the company's stock.

Insider Activity

In related news, CAO Erin Burkhart sold 1,786 shares of the company's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $59.31, for a total transaction of $105,927.66. Following the sale, the chief accounting officer now owns 14,173 shares in the company, valued at approximately $840,600.63. This represents a 11.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold 4,698 shares of company stock worth $308,172 over the last ninety days. Insiders own 0.85% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. UBS Group increased their price objective on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Wall Street Zen upgraded shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Bank of America raised their price target on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. Citigroup decreased their price objective on BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $90.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Six analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus price target of $93.45.

BioMarin Pharmaceutical Stock Down 0.7%

Shares of BioMarin Pharmaceutical stock traded down $0.43 during trading on Thursday, reaching $58.05. The stock had a trading volume of 532,483 shares, compared to its average volume of 1,868,110. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $11.13 billion, a price-to-earnings ratio of 26.41, a P/E/G ratio of 0.61 and a beta of 0.27. The stock has a fifty day moving average price of $62.97 and a two-hundred day moving average price of $64.91. BioMarin Pharmaceutical Inc. has a 52 week low of $52.93 and a 52 week high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. The firm had revenue of $747.31 million for the quarter, compared to analysts' expectations of $711.05 million. Sell-side analysts predict that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current fiscal year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.